Why These 3 ASX Stocks Captured Investors' Attention on Friday
Source: Kapitales Research
Highlights:
Silex Systems, Deep Yellow and Mesoblast emerged among the ASX's top gainers.
Strong sector sentiment supported gains in nuclear technology, uranium and biotechnology stocks.
Mesoblast's commercial update added momentum with record annual Ryoncil® revenue.
Investor interest spread across multiple sectors on Friday, with Silex Systems Limited, Deep Yellow Limited and Mesoblast Limited posting notable gains. Stocks in Focus
Silex Systems (ASX: SLX) gained 9.02% to close at AU$5.680
Silex Systems and Deep Yellow benefited from continued investor optimism surrounding the nuclear energy sector. Although neither company released a market-sensitive announcement during the session, both stocks attracted buying interest as investors remained focused on the long-term outlook for nuclear power, uranium demand and energy security.The global push toward cleaner energy sources and increasing interest in reliable baseload power continue to support sentiment across uranium producers and nuclear technology companies. Investors are also closely monitoring project developments, commercial opportunities and broader policy support for nuclear energy worldwide.
Mesoblast Delivers Strong Commercial Update
Unlike the other two gainers, Mesoblast's rally followed a positive business update. The biotechnology company reported Ryoncil® net revenue of US$36 million for the quarter ended 30 June 2026, taking full-year revenue to US$115 million, exceeding its initial commercial expectations. The company said strong uptake across major U.S. paediatric centres continued to drive revenue growth and reinforced confidence in its commercial strategy. It also highlighted a strengthened capital position supported by revenue growth and a new five-year financing facility.
Investors Continue Chasing Growth Themes
Friday's gains reflected continued investor appetite for companies positioned within high-growth industries, including advanced nuclear technology, uranium and biotechnology. While Mesoblast's move was supported by a company-specific update, broader sector optimism helped lift Silex Systems and Deep Yellow, demonstrating that investors remain willing to back businesses with long-term structural growth potential.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Why These 3 ASX Stocks Captured Investors' Attention on Friday
Highlights:
Investor interest spread across multiple sectors on Friday, with Silex Systems Limited, Deep Yellow Limited and Mesoblast Limited posting notable gains. Stocks in Focus
Nuclear-Themed Stocks Extend Their Momentum
Silex Systems and Deep Yellow benefited from continued investor optimism surrounding the nuclear energy sector. Although neither company released a market-sensitive announcement during the session, both stocks attracted buying interest as investors remained focused on the long-term outlook for nuclear power, uranium demand and energy security.The global push toward cleaner energy sources and increasing interest in reliable baseload power continue to support sentiment across uranium producers and nuclear technology companies. Investors are also closely monitoring project developments, commercial opportunities and broader policy support for nuclear energy worldwide.
Mesoblast Delivers Strong Commercial Update
Unlike the other two gainers, Mesoblast's rally followed a positive business update. The biotechnology company reported Ryoncil® net revenue of US$36 million for the quarter ended 30 June 2026, taking full-year revenue to US$115 million, exceeding its initial commercial expectations. The company said strong uptake across major U.S. paediatric centres continued to drive revenue growth and reinforced confidence in its commercial strategy. It also highlighted a strengthened capital position supported by revenue growth and a new five-year financing facility.
Investors Continue Chasing Growth Themes
Friday's gains reflected continued investor appetite for companies positioned within high-growth industries, including advanced nuclear technology, uranium and biotechnology. While Mesoblast's move was supported by a company-specific update, broader sector optimism helped lift Silex Systems and Deep Yellow, demonstrating that investors remain willing to back businesses with long-term structural growth potential.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au